Atezolizumab translates into survival benefit for bladder cancer patients with ctDNA positivity
With hospitalizations up, France weighs return to masks
2 July 2022New imaging technology less accurate than MRI at detecting prostate cancer, trial shows
4 July 2022Atezolizumab translates into survival benefit for bladder cancer patients with ctDNA positivity
Researchers who treated a group of post-surgery bladder cancer patients with the immunotherapy drug atezolizumab have found that patients whose blood contained circulating tumor DNA (ctDNA), responded very well to the treatment.
